# US 2013/0252929 A1 · Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252929 A1
- Document ID: US20130252929A1
- Status: Published application
- Kind: A1
- Application number: 13/990,373
- Filed: 2011-11-18
- Published: 2013-09-26
- Earliest claimed: 2010-11-29
- Assignees: Hanlim Pharmaceutical Co., Ltd.
- Inventors: Sang-Yong Lee; Geun-Hyeog Lee; Byong-Sun Choi; Jong-Hyeon Ryu; Jin-Ha Park; Mi-Jin O.
- Web page: https://patentgrep.com/patent/US20130252929A1

## CPC

- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 9/0043: {Nose}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.

## Claims

### Claim 1

A pharmaceutical composition for nasal administration comprising mometasone furoate azelastine hydrochloride and thaumatin for reducing bitterness and irritation.

### Claim 2 (depends on 1)

The pharmaceutical composition for nasal administration of claim 1, wherein the thaumatin is present in an amount from 0.1 to 0.5 w/v %.

### Claim 3 (depends on 1)

The pharmaceutical composition for nasal administration of claim 1, wherein the pharmaceutical composition comprises 0.01 to 1.0 w/v % of mometasone furoate; 0.05 to 1.0 w/v % of azelastine hydrochloride; 0.1 to 0.5 w/v % of thaumatin; 1.0 to 5.0 w/v % of a thickening agent; 0.2 to 0.6 w/v % of a buffering agent; 0.001 to 0.1 w/v % of a surfactant; 5.0 to 10.0 w/v % of an isotonic agent; 0.01 to 1.0 w/v % of a stabilizer; and 0.002 to 0.05 w/v % of a preservative, in an aqueous medium.

### Claim 4 (depends on 3)

The pharmaceutical composition for nasal administration of claim 3, wherein the pharmaceutical composition comprises 0.01 to 1.0 w/v % of mometasone furoate; 0.05 to 1.0 w/v % of azelastine hydrochloride; 0.1 to 0.5 w/v % of thaumatin; 1.0 to 5.0 w/v % of a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose; 0.2 to 0.6 w/v % of a mixture of citric acid and sodium citrate; 0.001 to 0.1 w/v % of polyoxyethylene sorbitan monooleate; 5.0 to 10.0 w/v % of a mixture of glycerin and sorbitol; 0.01 to 1.0 w/v % of sodium edetate; and 0.002 to 0.05 w/v % of benzalkonium chloride, in an aqueous medium.

### Claim 5 (depends on 4)

The pharmaceutical composition for nasal administration of claim 4, wherein the pharmaceutical composition consists of 0.05 w/v % of mometasone furoate;

### Claim at position 6

14 w/v % of azelastine hydrochloride; 0.25 w/v % of thaumatin; 2.0 w/v % of a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose; 0.2 w/v % of citric acid; 0.28 w/v % of sodium citrate; 0.01 w/v % of polyoxyethylene sorbitan monooleate; 2.1 w/v % of glycerin; 6.6 w/v % of sorbitol; 0.1 w/v % of sodium edetate; 0.02 w/v % of benzalkonium chloride; and the remaining amount of water.

### Claim 6 (depends on 1)

The pharmaceutical composition for nasal administration according to claim 1, wherein the pharmaceutical composition is formulated into a nasal spray form.

### Claim 7 (depends on 2)

The pharmaceutical composition for nasal administration according to claim 2, wherein the pharmaceutical composition is formulated into a nasal spray form.

### Claim 8 (depends on 3)

The pharmaceutical composition for nasal administration according to claim 3, wherein the pharmaceutical composition is formulated into a nasal spray form.

### Claim 9 (depends on 4)

The pharmaceutical composition for nasal administration according claim 4, wherein the pharmaceutical composition is formulated into a nasal spray form.

### Claim 10 (depends on 5)

The pharmaceutical composition for nasal administration according claim 5, wherein the pharmaceutical composition is formulated into a nasal spray form.
